Company Overview
Company Type: Public Company
Website: satellos.com
Number of Employees: 6
Ticker: MSCL (TSXV)
Year Founded: 2018


Business Description
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of duchenne. The company’s MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
47.4
EBITDA
(8.6)
Total Enterprise Value
0.7
TEV/EBITDA
NM
EBIT
(8.8)
Cash & ST Invst.
48.7
P/Diluted EPS Before Extra
NM
Net Income
(12.8)
Total Debt
2.1
Price/Tang BV
1.0x
Capital Expenditure
0.0
Total Assets
53.1
Total Debt/EBITDA
NM




Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Oct-10-2023


Estimates Snapshot (Current Fiscal Year End: Dec-31-2023 | Currency: CAD)
Periodic Estimates
Current FQ
Current FQ+1
Current FY
Current FY+1
NTM
EPS (GAAP)
(0.03)
(0.03)
(0.12)
(0.08)
(0.10)
Revenue (mm)
0.00
0.00
0.00
0.00
0.00

Forward Multiples (Current FY)

Price/Earnings
NM

Non-Periodic Estimates

Recommendation
No Opinion (0.00)
Target Price
0.95
Potential Upside
133.33%


Key Professionals
Name
Title
Gleeson, Francis 
Co-Founder, CEO, President & Director
Rudnicki, Michael A.
Co-Founder & Chief Scientific Officer
Williams, Elizabeth 
Chief Financial Officer
Lambert, Philip 
Chief Technology Officer
Hall, J. Robert
Senior Vice President of Finance & Administration
Chan, Desiree 
Chief of Staff
Jacobs, Alan 
Chief Medical Officer
Jarosz, William Wasyl
Executive Director
Liggett, Michael 
Strategic Advisor
Whitehead, Warren 
Head of Corporate Strategy

Key Board Members
Name
Title
MacKay, Geoff 
Independent Chairman of the Board of Directors
Gleeson, Francis 
Co-Founder, CEO, President & Director
Jarosz, William Wasyl
Executive Director
Mostafa, Adam S.
Independent Director
Al-awar, Rima 
Independent Director
Berger, Franklin M.
Independent Director
Bloom, Brian Matthew
Independent Director
McVicar, William K.
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
79 Wellington Street West 33rd Floor | Toronto, ON | M5K 1N2  | Canada
Phone: 647-660-1780   

Current and Pending Investors
Parent Project Muscular Dystrophy

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.41
Market Cap (mm)
46.2
Open
 0.41
Shares Out. (mm)
112.8
Previous Close
 0.41
Float %
78.1%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(2.4)%
Dividend Yield %
-
Day High/Low
 0.42/ 0.40
Diluted EPS Excl. Extra Items
(0.26)
52 wk High/Low
 0.85/ 0.22
P/Diluted EPS Before Extra
NM
Volume (mm)
0.04
Avg 3M Dly Vlm (mm)
0.10
Beta 5Y
0.58


 
Delayed Quote** | Last Updated on Oct-11-2023 12:00 AM (GMT-5)
TSXV:MSCL - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
iCo Therapeutics Inc.
As of August 13, 2021, iCo Therapeutics Inc. was acquired by Satellos Bioscience Inc., in a reverse merger transaction. iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat ocular and infectious diseases. Its in-licensed drug candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat ulcerative colitis and bullous pemphigoid; and Oral AmpB Delivery System, an oral formulation of Amphotericin B that is in Phase 1b clinical trial for the treatment of systemic fungal and parasitic infections. The company was incorporated in 2005 and is headquartered in Vancouver, Canada.

United States and Canada
Biotechnology
-
7.00
0.00
Amphotericin B Technologies, Inc.
Amphotericin B Technologies, Inc. develops an anti-fungal agent used to treat serious fungal infections. The company was incorporated in 2021 and is based in Vancouver, Canada. Amphotericin B Technologies, Inc. operates as a subsidiary of Satellos Bioscience Inc.

United States and Canada
Pharmaceuticals
-
-
-
iCo Therapeutics Australia Pty Ltd.
iCo Therapeutics Australia Pty Ltd. operates as a subsidiary of iCo Therapeutics Inc.

Asia / Pacific
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-10-2023
May-25-2023
Private Placement
Target
Satellos Bioscience Inc. (TSXV:MSCL)


32.67
Apr-18-2023
May-17-2023
Public Offering
Target
Satellos Bioscience Inc. (TSXV:MSCL)


40.82
Mar-15-2023
Mar-29-2023
Private Placement
Target
Satellos Bioscience Inc. (TSXV:MSCL)


1.76
Jul-11-2022
Sep-13-2022
Public Offering
Target
Satellos Bioscience Inc. (TSXV:MSCL)


3.81
Mar-22-2021
Apr-27-2021
Private Placement
Target
Satellos Bioscience Inc. (TSXV:MSCL)


5.84
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-27-2023
Company Conference Presentations
Satellos Bioscience Inc. Presents at Cantor Fitzgerald Annual Global Healthcare Conference 2023, Sep-27-2023 02:25 PM
Sep-05-2023
Executive/Board Changes - Other
Satellos Bioscience Inc. Announces Appointment of Warren Whitehead as Head of Corporate Strategy
Sep-05-2023
Executive Changes - CFO
Satellos Bioscience Inc. Announces CFO Changes
Jun-29-2023
Annual General Meeting
Satellos Bioscience Inc., Annual General Meeting, Jun 29, 2023
Jun-29-2023
Shareholder/Analyst Calls
Satellos Bioscience Inc. - Shareholder/Analyst Call

M&A Advisors
Borden Ladner Gervais LLP, Leede Jones Gable Inc.


Advisors
Most Recent Auditor
MNP LLP
M&A Advisors
Borden Ladner Gervais LLP, Leede Jones Gable Inc.
Private Placement Advisors
Bloom Burton & Co. Inc.
Public Offering Advisors
Borden Ladner Gervais LLP, MNP LLP, Montgomery, Barnett, Brown, Read, Hammond & Mintz, LLP, PricewaterhouseCoopers LLP, Chartered Accountants


Most Recent Auditor
Meyers Norris Penny LLP - MNP LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Crystal Research Associates LLC
Kraws, Jeffrey Jay
Oct 05, 2023 01:12 PM
MSCL
NEW EXECUTIVE INFORMATIONAL OVERVIEW: SATELLOS BIOSCIENCE INC. (MSCL-TSXV/MSCLF-OTCQB)
Initiation of Coverage*
62
ValuEngine, Inc.

Oct 02, 2023 06:25 AM
MSCL
ValuEngine - Toronto Quantitative Stock Report for MSCL
Reports
5
MarketLine

Sep 20, 2023 06:01 AM
MSCL
Satellos Bioscience Inc
Reports
32
Zacks Small-Cap Research
Bautz, David
Sep 14, 2023 08:26 AM
MSCL
MSCLF: SAT-3153 Granted Orphan Drug Designation and Rare Pediatric Disease Designation
Reports
6
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jul 12, 2023 06:00 PM
MSCL
Rating Update for Satellos Bioscience Inc
EPS Estimates*
3
SADIF-Investment Analytics S.A.
SADIF-Investment Analytics Research Team
Jun 25, 2023 06:00 PM
MSCL
Rating Update for Satellos Bioscience Inc
EPS Estimates*
3
Zacks Small-Cap Research
Bautz, David
Jun 14, 2023 09:01 AM
MSCL
MSCLF: Raises Gross Proceeds of 55 Million
Reports
7
Zacks Small-Cap Research
Bautz, David
Apr 04, 2023 03:01 PM
MSCL
MSCLF: Preclinical Proof-of-Concept Data for SAT-3153 Presented at MDA Conference
Reports
7
Zacks Small-Cap Research
Bautz, David
Feb 07, 2023 09:00 AM
MSCL
SAT-3153 Selected as Lead Development Candidate
Reports
7
Zacks Small-Cap Research
Bautz, David
Nov 09, 2022 08:01 AM
MSCL
We are initiating coverage of Satellos Biosciences Inc. (MSCLF) with a $0.70 valuation.
Initiation of Coverage*
21


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Bloom Burton Investment Group Inc.

8,490,070

7.53

3.6

May-29-2023


Berger BA, C.F.A., MA, MBA, Franklin M.

6,809,000

6.04

2.9

Jun-29-2023


Gleeson B.B.A. M.B.A, Francis 

3,740,389

3.32

1.6

Sep-07-2023


Rudnicki Ph.D., Michael A.

3,084,220

2.73

1.3

Jun-01-2023


Jarosz, William Wasyl

1,711,374

1.52

0.7

Jun-01-2023


Bloom, Brian Matthew

664,906

0.59

0.3

Sep-07-2023


Hall CFA, J. Robert

80,000

0.07

0.0

Sep-07-2023


MacKay BSc, Geoff 

70,422

0.06

0.0

Jun-01-2023


McVicar Ph.D., William K.

25,000

0.02

0.0

May-29-2023


Williams CA, CPA, Elizabeth 

20,000

0.02

0.0

Sep-08-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Berger BA, C.F.A., MA, MBA, Franklin M.
6,809,000
6,809,000
Bloom Burton Investment Group Inc.
8,490,070
1,453,070
Jarosz, William Wasyl
1,711,374
1,240,000
Gleeson B.B.A. M.B.A, Francis 
3,740,389
100,000
Hall CFA, J. Robert
80,000
80,000
Bloom, Brian Matthew
664,906
35,094
McVicar Ph.D., William K.
25,000
25,000
Williams CA, CPA, Elizabeth 
20,000
20,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Drug Therapeutic Products, MyoReGenX Assay Platform, SAT-3153 (Future)


Upcoming Events
Date/Time
Type
Nov-23-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-20-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
News Releases
38 KB
Sep-07-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
News Releases
50 KB
Sep-05-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
News Releases
55 KB
Aug-29-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
News Releases
374 KB
Aug-28-2023
Jun-30-2023
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
Interim Financial Statements
1 MB
Aug-09-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
News Releases
31 KB
Jun-30-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
News Releases
46 KB
Jun-07-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
News Releases
46 KB
Jun-05-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
Management Proxy Materials
71 KB
Jun-05-2023
-
Satellos Bioscience Inc. (TSXV:MSCL)
SEDAR
Management Proxy Materials
70 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Williams CA, CPA, Elizabeth  (Chief Financial Officer)
Sep-08-2023
New Common Shares
20,000
9,962
Open Market Acquisition
New
Multiple
-
Sep-08-2023
New Common Shares
4,000
1,956
Open Market Acquisition
-
Exchange Announcement
-
Sep-08-2023
New Common Shares
2,000
1,018
Open Market Acquisition
-
Exchange Announcement
-
Sep-08-2023
New Common Shares
14,000
6,987
Open Market Acquisition
-
Exchange Announcement
Gleeson B.B.A. M.B.A, Francis  (Co-Founder, CEO, President & Director)
Sep-07-2023
New Common Shares
100,000
45,224
Open Market Acquisition
2.75
Multiple
-
Sep-07-2023
New Common Shares
25,000
10,567
Open Market Acquisition
-
Exchange Announcement
-
Sep-07-2023
New Common Shares
25,000
11,191
Open Market Acquisition
-
Exchange Announcement
-
Sep-07-2023
New Common Shares
25,000
11,422
Open Market Acquisition
-
Exchange Announcement
-
Sep-07-2023
New Common Shares
6,500
3,103
Open Market Acquisition
-
Exchange Announcement
-
Sep-07-2023
New Common Shares
18,500
8,942
Open Market Acquisition
-
Exchange Announcement
Bloom, Brian Matthew (Independent Director)
Sep-07-2023
New Common Shares
80,000
37,855
Open Market Acquisition
13.68
Multiple
-
Sep-07-2023
New Common Shares
16,000
7,571
Open Market Acquisition
-
Exchange Announcement
-
Sep-07-2023
New Common Shares
64,000
30,284
Open Market Acquisition
-
Exchange Announcement
Gleeson B.B.A. M.B.A, Francis  (Co-Founder, CEO, President & Director)
May-17-2023
New Common Shares
200,000
100,950
Open Market Acquisition
5.81
Multiple
Hall CFA, J. Robert (Senior Vice President of Finance & Administration)
May-17-2023
New Common Shares
80,000
40,380
Open Market Acquisition
New
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
MacKay, Geoff 
Independent Chairman of the Board of Directors
647-660-1780
-

Gleeson, Francis 
Co-Founder, CEO, President & Director
647.660.1780
-
frank@dlvrtherapeutics.ca
Jarosz, William Wasyl
Executive Director
(917) 692-8799
-
bill.jarosz@cartesiangroup.com
Mostafa, Adam S.
Independent Director
647-660-1780
-

Al-awar, Rima 
Independent Director
647-660-1780
-

Berger, Franklin M.
Independent Director
647-660-1780
-

Bloom, Brian Matthew
Independent Director
(416) 640-7580
-
bbloom@bloomburton.com
McVicar, William K.
Independent Director
647-660-1780
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Gleeson, Francis 
Co-Founder, CEO, President & Director
647.660.1780
-
frank@dlvrtherapeutics.ca
Rudnicki, Michael A.
Co-Founder & Chief Scientific Officer
647-660-1780
-

Williams, Elizabeth 
Chief Financial Officer
416-648-5555
-

Lambert, Philip 
Chief Technology Officer
647-660-1780
-

Hall, J. Robert
Senior Vice President of Finance & Administration
(437) 836-3244
-
rhall@htx.ca
Chan, Desiree 
Chief of Staff
647-660-1780
-

Jacobs, Alan 
Chief Medical Officer
647-660-1780
-

Jarosz, William Wasyl
Executive Director
(917) 692-8799
-
bill.jarosz@cartesiangroup.com
Liggett, Michael 
Strategic Advisor
(778) 802-9806
-
liggett@icotherapeutics.com.
Whitehead, Warren 
Head of Corporate Strategy
647-660-1780
-
warren.whitehead@amorfix.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
